News – Page 1064 – Endpoints News

Anatomy of a $9B buyout: Celgene’s quick turn from Juno’s close collaborator to new owner

8 years ago

Hans Bishop gets a $287M payday as Juno execs see windfall fortunes — with a $922M payoff for Arch

8 years ago

Slammed by a trial hold, Intarcia terminates studies and axes staff in wake of an FDA rejection

8 years ago

Buyout buzz hits fever pitch on report that Nektar is ‘exploring options’

8 years ago

Kenji Yasukawa takes the reins at Astellas; Voyager hunts for new CEO as Steven Paul goes back to research

8 years ago

Billion-dollar biosim maker mulls $500M Hong Kong IPO

8 years ago

Voyager co-founder Steven Paul steps down from CEO seat; Alnylam enters final stretch at the FDA with patisiran

8 years ago

RNA biotech Arcturus boots CEO Joseph Payne

8 years ago

Amgen’s $70B in ‘deal capacity’ post-tax reform puts the spotlight on 'big things' in M&A — analyst

8 years ago

AstraZeneca sweeps out a PhIII asthma flop, a PD-1 drug and some other rejects as Q4 tally disappoints

8 years ago

After EMA flop, Puma takes Nerlynx to China in new out-licensing deal

8 years ago

Moderna boosts unicorn status with a whopping $500M raise and $7B valuation

8 years ago

UCB, investors back a neurosciences startup called Syndesi; Germany's Biofrontera increases US IPO pricing range

8 years ago

Think your odds of R&D success are miserable? MIT’s Andrew Lo might have a surprise for you

8 years ago

Nuclear scare to fuel anti-radiation drug sales? PTx buys ex-Sanofi drug just in case

8 years ago

Puma touts its latest advances in a basket trial for Nerlynx, as Europeans appear ready to reject the drug

8 years ago

Roche silently scraps two one-time blockbuster hopefuls as $725M Seragon deal craters

8 years ago

With a potential cure for lysosomal storage disorders in hand, Avrobio raises $60M to back gene therapy pipeline

8 years ago

Vertex execs whip up a cheer from the analysts after hedging their bet by picking their two top triples for PhIII

8 years ago

NIH, Fox Foundation allies with biopharmas on $24M Parkinson's project; FDA accepts Theravance/Mylan NDA for COPD ...

8 years ago

Startup with Johns Hopkins roots raising $40.5 million to develop cancer metabolism drugs

8 years ago

Analysis: Pfizer tallies an impressive array of late-stage catalysts for cancer, gene therapies and more

8 years ago

Restless Seattle Genetics snaps up a pivotal-stage cancer drug with $614M Cascadian buyout pact

8 years ago

Focused on blockbuster indications, Sage touts evidence that 217 could work on insomnia

8 years ago

First page Previous page 1061 1062 106310641065 1066 1067 Next page Last page